TABLE OF CONTENTS
STAY CONNECTED
EXPLORE MORE
- Compliance (5)
- Mergers and Acquisition (1)
- News (1)
- Secure Collaboration (9)
- Self Provisioning (3)
- Uncategorized (1)
- Virtual Data Room (24)
Introduction
Clinical trials generate massive amounts of sensitive data, and securely sharing this information with stakeholders is essential for success.
When it comes to ensuring data integrity and confidentiality during clinical trials, having the right technology to manage and share information is critical. Govern 365’s Data Room functionality offers a secure, compliant, and efficient platform for managing clinical trial data throughout its lifecycle.
Key Benefits
1. Secure Data Sharing
Govern 365 allows life sciences companies to share sensitive trial data with stakeholders while maintaining tight security controls. Built-in encryption and user-based access permissions ensure only authorized users can access specific files.
2. Version Control
Clinical trials often require multiple updates to datasets, protocols, and reports. With Govern 365’s version control, stakeholders can easily track changes, ensuring the right version is always being reviewed or referenced.
3. Audit Trail for Compliance
Clinical trials are subject to strict regulatory requirements and having a clear audit trail of who accessed or modified data can help streamline compliance processes. Govern 365 automatically logs all activity, providing a transparent history of document handling.
4. Easy Collaboration with External Parties
Whether collaborating with research organizations or regulatory bodies, Govern 365 enables secure collaboration with external teams without compromising data security. External users can be given specific permissions, ensuring sensitive data is always protected.
Conclusion
In an industry where data security and compliance are paramount, Govern 365 provides life sciences companies with the tools to securely manage and share clinical trial data, ultimately speeding up the research process and reducing risk. For more details, please reach out to us.